Those receiving budesonide-glycopyrrolate ... a twice-daily metered dose inhaler, and fluticasone-umeclidinium-vilanterol, a once-daily dry powder inhaler for treatment of COPD in routine clinical ...

The paper, ‘Single inhaler extra fine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised ...

AstraZeneca may mount a challenge to GlaxoSmithKline’s three-in-one inhaler for chronic obstructive pulmonary disease ... and Chiesi also has a rival triple therapy approved in Europe.

Metered-dose inhaler budesonide-glycopyrrolate-formoterol ... The other single-inhaler on the market for COPD triple therapy, fluticasone-umeclidinium-vilanterol, is a dry-powder inhaler that ...

Developed in partnership with Innoviva, Trelegy is the first ever daily single-inhaler to combine a triple therapy for COPD, and could help patients manage their condition better. Around a quarter ...

Do inhaled corticosteroids elevate risk for pneumonia in patients with chronic obstructive pulmonary disease? Several clinical trials, observational studies, and meta-analyses suggest that they do ...